Pulmonary exacerbations in cystic fibrosis (CF) remain poorly understood and treatment is usually targeted at Pseudomonas aeruginosa. Within Australia a predominant shared P. aeruginosa strain (AUST-02) is associated with greater treatment needs. This single centre study assessed temporal shared strain population dynamics during and after antibiotic treatment of exacerbations. Sputum was collected from 12 adult patients with a history of chronic AUST-02 infection at four time-points during and after treatment of an exacerbation. Forty-eight P. aeruginosa isolates within each sample underwent AUST-02 allele-specific PCR and SNP-based strain genotyping. Various commonly shared Australian strains (AUST-01, 0.1%; AUST-02, 54.3%; AUST-06, 36.6%; AUST-07, 4.6%; AUST-11, 4.3%) and two unique strains (0.1%) were identified from 45 sputum samples (2160 isolates). Based on within-patient relative abundance of strains, a “single-strain infection” (n = 7) or “mixed-strain infection” (n = 5) was assigned to each patient. A significant temporal variation in the P. aeruginosa population composition was found for those with mixed-strain infection (P < 0.001). Patients with mixed-strain infections had more long-term treatment requirements than those with single-strain infection. Moreover, despite both groups having similar lung function at study entry, patients with single-strain infection had greater improvement in FEV1% predicted following their exacerbation treatment (P = 0.02). Pulmonary exacerbations may reveal multiple, unrelated P. aeruginosa strains whose relative abundance with one another may change rapidly, in a sustained and unpredictable manner.
Background: The global incidence of rapidly growing mycobacterial (RGM) infections is rising. We examined cases of extrapulmonary RGM infection in Far North Queensland (FNQ), tropical Australia, to characterise their presentation and the challenges in their management. Methods: All RGM isolated from extrapulmonary sites in FNQ residents between January 2008 and December 2024 were identified; the isolates’ microbiological characteristics and the patients’ clinical course were reviewed. Results: Mycobacterium fortuitum group (51/144, 35%), Mycobacterium abscessus complex (45/144, 31%) and Mycobacterium chelonae (30/144, 21%) were the most frequently isolated RGM. Clinical infection was confirmed in 103/144 (72%) isolates. The annual incidence of RGM clinical infections increased over the study period from 0.4 to 2.4/100,000 population (rs=0.57, p=0.02). Patients had a median (interquartile range (IQR)) age of 52 (33-66) years; 10/103 (10%) were immunosuppressed while only 6/103 (6%) had other significant comorbidity. Preceding environmental trauma was documented in 39/103 (38%), 38/103 (37%) followed surgery and 23/103 (22%) infections involved prosthetic material. The median (IQR) duration of symptoms at diagnosis was 5 (2-12) weeks. Antimicrobial susceptibility testing demonstrated high rates of resistance; 78 patients were treated with antibiotics for a median (IQR) duration of 18 (16-24) weeks with 47/78 (60%) experiencing an adverse drug reaction. Surgical management was necessary in 64/103 (62%). There were 6 microbiologically-confirmed relapses but no deaths directly attributable to the infection or its treatment. Conclusion: Extrapulmonary RGM infections are increasing in frequency in tropical Australia and predominantly affect younger, healthy individuals. Delayed diagnosis and adverse events from antimicrobial therapy are common.